BrilgID Biologics

We have developed a novel drug discovery platform to tackle serious fungal infections. Using this platform, we have generated human monoclonal antibodies (mAbs) against fungal cell wall components which play crucial roles in infection and drug resistance. In “clinically predictive” animal models of infection, our lead mAbs have shown superior protection by increasing mice survival and decreasing fungal burden in multiple organs. We propose these antibodies as a first-in-class therapy against life-threatening fungal infections. Currently, these infections have poor clinical outcomes due to treatment failure in high-risk groups including cancer patients, solid organ transplantation and infections that are multidrug resistant.